Two biotechs target dry eye disease after Novartis’ Xiidra problemsThe pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, Share XTwo biotechs target dry eye disease after Novartis’ Xiidra problemshttps://pharmaphorum.com/news/two-biotechs/
Boehringer bags CHMP backing for Ofev in rare lung diseaseBoehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the Share XBoehringer bags CHMP backing for Ofev in rare lung diseasehttps://pharmaphorum.com/news/boehringer-bags-chmp-backing-for-ofev-in-rare-lung-disease/
Jazz targets US launch of SCLC drug after FDA grants fast reviewPharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for Share XJazz targets US launch of SCLC drug after FDA grants fast reviewhttps://pharmaphorum.com/news/jazz-targets-us-launch-of-sclc-drug-after-fda-grants-fast-review/
PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinSpain’s PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin Share XPharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinhttps://pharmaphorum.com/news/pharmamar-and-jazz-sign-1bn-us-deal-for-lung-cancer-drug/
